Abiraterone Acetate Trial in African American Prostate Cancer Patients

Inclusion Criteria: * 1\. Have signed an informed consent document indicating that the subjects understands the purpose of and procedures required for the study and are willing to participate in the study * Be willing/able to adhere to the prohibitions and restrictions specified in this protocol * Written Authorization for Use and Release of Health and Research Study Information * African American or Black (by self identification) * Male aged 18 years and above * Histologically or cytologically confirmed adenocarcinoma of the prostate * Metastatic disease documented by standard imaging * Progressive prostate cancer based on either rising PSA, new bone metastases, or progression of measurable disease according to PCWG2 12 guidelines. * Patients in either of the following clinical states will be eligible for enrollment: i. No prior chemotherapy; ii. Patients previously treated with 1-2 prior chemotherapy regimens permitted, one of which must have been included docetaxel * Surgically or medically castrated, with testosterone levels of \< 50 ng/dl. * Patients previously treated with an anti-androgen must demonstrate progression off of the anti-androgen. * Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2 * Have a baseline serum potassium of ≥ 3.5 mEq/L * Have aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin levels \< 1.5 x ULN * Have a serum albumin of ≥ 3.0 g/dL * Total bilirubin ≤ 1.5 x ULN * Have a platelet count of ≥ 100,000/μL * Have an absolute neutrophil count of \> 1500 cell/mm3 * Have a calculated creatinine clearance ≥ 60 mL/min * Have a hemoglobin of ≥ 9.0 g/dL * Able to swallow the study drug as a whole tablet * Willing to take abiraterone acetate on an empty stomach; no food should be consumed at least two hours before and for at least one hour after the dose of abiraterone acetate is taken * Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator during the study and for 1 week after last dose of abiraterone acetate Exclusion Criteria: * Active infection or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated * Known brain metastasis * Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg) Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment * Active or symptomatic viral hepatitis or chronic liver disease * History of pituitary or adrenal dysfunction * Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class III-IV heart disease or cardiac ejection fraction measurement of \< 50% at baseline * Administration of an investigational therapeutic within 30 days of screening * Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements * Have poorly controlled diabetes * Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents * Have a pre-existing condition that warrants long-term corticosteroid use in excess of study dose * Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients